Evan Paul

Evan is a dynamic biomedical scientist with over 15 years of experience conducting research in molecular biology and analytical chemistry, with an emphasis on discovering novel biomarkers and therapeutic targets.

He received a dual Ph.D. in Integrative Physiology and Neuroscience from the University of Colorado Boulder, USA, where he directed an analytical chemistry core unit to detect small molecule neurotransmitters in the brain. He also received a minor degree in Business Administration. He continued his research as a postdoc in Alon Chen’s prestigious laboratory jointly sponsored by the Max Planck Institute of Psychiatry in Munich, Germany, and the Weizmann Institute of Science in Rehovot, Israel. There he developed protocols using next-generation sequencing and in situ hybridization to quantify and visualize, respectively, microRNAs in order to identify novel biomarkers for psychiatric disorders.

He has published 25+ scientific papers and book chapters in prestigious journals like Nature Neuroscience and Neuron, with the latter resulting in a patent for a novel microRNA biomarker for depression that was licensed to miCure therapeutics Ltd.